Severe Neonatal Hyperparathyroidism due to a Novel Homozygous Mutation of the Calcium-Sensing Receptor (CaSR)

Amir Hacohen-Solovitz1, Yardena Tenenbaum-Rakover1,2, Ronen Spiegel1,3, Jeffrey Weinberger4, David Gillis5, Gershon Goor Zamir6, Michael A. Levine7, Tal Almagor1,2

1Pediatric Department B, Ha’Emek Medical Center, Afula, Israel; 2Pediatric Endocrine Institute, Ha’Emek Medical Center, Afula, Israel; 3Rappaport Faculty of Medicine, Technion, Haifa, Israel; 4Department of Otolaryngology and Neck Surgery, Hadassah–Hebrew University Medical Center, Jerusalem, Israel; 5Department of Pediatrics, Hadassah – Hebrew University Medical Center, Jerusalem, Israel; 6Pediatric Intensive Care Unit, Ha’Emek Medical Center, Afula, Israel; 7Center for Bone Health, Division of Endocrinology and Diabetes, Children’s Hospital of Philadelphia, PA, USA

Background
Homozygous loss-of-function mutations of the CaSR are associated with neonatal severe hyperparathyroidism (NSHPT), a life-threatening condition with a challenging treatment approach.

Case description
A 7-day-old-female infant admitted to our Pediatric Department due to feeding difficulties, lethargy and hypotonicity. Laboratory evaluation revealed:
- Extreme hypercalcemia of 23.54 mg/dL (7.6–10.4)
- Low phosphorus levels of 2.16 mg/dL (4.0–6.5)
- High PTH of 568 pg/mL (18.4–80.1)
- Skeletal survey revealed bone deformities with evidence of growth-plate injury and severe osteopenia.

These findings indicate NSHPT.


Treatment
Treatment was initiated with aggressive hydration, bisphosphonate IV and calcitonin for the first 24 hours that reduced calcium levels to normal range within days.

Cinacalcet was initiated at a dose of 0.35 mg/kg per day with an increase up to 7.5 mg/kg per day.

Despite normal calcium levels, PTH remained elevated and progressive bone disease was demonstrated.

At 9 weeks of age, total parathyroidectomy with auto-transplantation of one gland in the thigh was performed. Later she developed hypoparathyroidism with hypocalcemia of 5.94 (9-11) that necessitated oral calcium and alfacalcidol therapy.

Today, at the age of 11 months, the toddler is developing well and maintains normal calcium levels.

Conclusions
- This case report demonstrates the challenges of treating NSHPT and indicates that the therapeutic goal must be to reduce serum levels of both calcium and PTH, as elevated PTH by itself can cause severe bone deformities.
- Cinacalcet treatment should be considered as initial treatment, but if it is ineffective, a definitive hyperparathyroidectomy surgery should not be delayed.